Lots in the papers this morning about the US company, Geron, halting its stem cell study on spinal cord injury. I thought I would share this coverage from the Washington Post. Geron's decision highlights a lot of interesting issues around science funding.. ..the long-term nature of science ...the difficulties for the private sector in keeping … Continue reading Washington Post coverage of Geron halting its stem cell trial on spinal cord injury
biotechs
An evening of industry – how the pharma business model is changing
So it's 10pm and I'm busy here putting the final touches to the AMRC/INVOLVE report of the workshop we held in November which drew together patient views on health research regulation. This was at the invitation of the Academy of Medical Sciences as part of their review of regulation and governance but - and all … Continue reading An evening of industry – how the pharma business model is changing
simondenegri.com 